Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |
Manasa Swapna K. R*, Dr. M. Siddaiah1
*Research scholar, Bhagwant University, Sikar Road, Ajmer, Rajasthan-305004
1Department of Pharmaceutics, JNTUA, Anantapur, Andhra Pradesh
A B S T R A C T
In this study, new formulations of nanoparticles like dispersed liquid dosage forms (metered dose inhalers and nebulizers) or dry powders were found to be the best formulations for the treatment of pulmonary disorders [6]. Nanoparticles as drug carrier may reduce the toxicity of the incorporated drug. Nanoparticles in the treatment of pulmonary disorders gained much importance due to its unique features like surface to mass ratio, ability to absorb, creates a large surface area to carry various compounds [8]. The prepared formulations can be formulated as DPIs that releases the drug directly into the lung efficiently for the treatment of asthma. The formulations (TBS – A (sd), ITZ – A (sd), TBS: ITZ – A (sd)) were the best formulations based on MMAD values and in-vitro dissolution. Combination powders TBS: ITZ – A (sd) may provide simultaneous delivery to the same site of action increasing the potential effect of the drugs. The study compared different DPI formulations of Terbutaline sulphate and Itraconazole in single and combined formulation to analyze the in-vivo distribution characteristics and stability. Combination powders may provide simultaneous delivery to the same site of action increasing the potential effect of the drugs. The powders reported here offer a novel formulation for localizing potent drugs as single agents or in combination for the treatment of asthma.
Keywords: Terbutaline sulphate, Itraconazole, Nanoparticles, asthma
